Miach Orthopaedics said today that it tapped a pair of executives to oversee the quality systems and clinical program for the knee ligament repair device it’s developing.
Miach is working on bio-engineered implants for surgical connective tissue repair, aiming first at anterior cruciate ligament repair with its Bridge-Enhanced ACL Repair device, a sponge that’s designed to act as a scaffold to stimulate healing. The Westborough, Mass.-based company said today that it named medtech veteran Michael O’Hara as quality assurance VP and Rita Paparazzo, formerly of Boston Biomedical Assoc. and Inverness Medical/Biosite, as clinical operations senior director.
“We are building a team of hard-working, collaborative, innovative employees at Miach,” president & CEO Martha Shadan said in prepared remarks. “Mike and Rita are results-driven individuals with substantial experience in their respective areas.”
Miach, which raised $23 million last September, in March touted a study showing results similar to traditional ACL repair at two years.
Trice Medical promotes Foster to CEO
Trice Medical said it’s promoting president Mark Foster to the corner office effective June 30, after the retirement of Jeffrey F. O’Donnell Sr. Foster is a veteran of Smith & Nephew (NYSE:SNN) and Boston Scientific (NYSE:BSX); O’Donnell is slated to stay on as a strategic advisor, the Malvern, Pa.-based company said.
Acelity promotes from within for COO, global president roles
Acelity said yesterday that it promoted CCO Gaurav Agarwal to president & COO and Chief Operating Officer. raised Americas president Rohit Kashyapto global commercial president.
Batelle lures DARPA scientist
Independent R&D shop Batelle said it named Justin Sanchez, formerly biological technologies office director at the U.S. Defense Dept.’s Defense Advanced Research Projects Agency, as a technical fellow to guide its life sciences research business.
Verrix preps for commercialization with regulatory, R&D VP nods
Sterility assurance firm Verrix said it named Kok-Hwee Ng as R&D VP and Aiying Sun as regulatory & quality VP as it readies its EVA biological indicator system for commercialization. San Clemente, Calif.-based Verrix raised an $8 million Series A round late last year.